(firstQuint)ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer.

 This is a single-arm, non-randomized study of ARQ 501 in combination with gemcitabine in adult patients with treatment-naive, unresectable, metastatic pancreatic adenocarcinoma.

 The study objectives are: Primary Objective: - Assess the overall response rate (ORR) of patients treated with ARQ 501 in combination with gemcitabine.

 Secondary Objectives: - Determine time to tumor progression (TTP) of patients treated with ARQ 501 in combination with gemcitabine - Further characterize the safety of ARQ 501 in combination with gemcitabine.

 ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer@highlight

The study will document the safety and efficacy of the combination of ARQ 501 and gemcitabine in patients with treatment-naive, unresectable, metastatic pancreatic adenocarcinoma.

